This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2013 Nov;52(8):1589-92.

doi: 10.3109/0284186X.2013.821206.

What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?

Gunnar Steineck¹, Bengt Glimelius

Affiliations

Affiliation

¹ Division of Clinical Cancer Epidemiology, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital , Gothenburg.

PMID: 24102178
DOI: 10.3109/0284186X.2013.821206

Editorial

What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?

Gunnar Steineck et al. Acta Oncol. 2013 Nov.

. 2013 Nov;52(8):1589-92.

doi: 10.3109/0284186X.2013.821206.

Authors

Gunnar Steineck¹, Bengt Glimelius

Affiliation

¹ Division of Clinical Cancer Epidemiology, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital , Gothenburg.

PMID: 24102178
DOI: 10.3109/0284186X.2013.821206

No abstract available

PubMed Disclaimer

Comment on

Population-based study on use of chemotherapy in men with castration resistant prostate cancer.
Lissbrant IF, Garmo H, Widmark A, Stattin P. Lissbrant IF, et al. Acta Oncol. 2013 Nov;52(8):1593-601. doi: 10.3109/0284186X.2013.770164. Epub 2013 Feb 21. Acta Oncol. 2013. PMID: 23427879 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Other Literature Sources
- scite Smart Citations